Raise closed, search for fresh raises on Seedstage

Dallas, TX

Developing secure biometric-controlled medication dispensing solutions to improve adherence and accessibility for chronic disease treatment.

• Targeting a Critical Need: COPA is designed to improve adherence and accessibility for Opioid Use Disorder treatment.
• NIH-Backed Innovation: Secured a $2M NIH research grant with potential for additional funding.
• Strong Regulatory Progress: Multiple FDA pre-submission meetings and a clear path to marketing authorization.
• Proven Intellectual Property: 19 issued patents protecting COPA’s unique biometric-controlled dispensing.
• Experienced Leadership: Led by a team with decades of expertise in healthcare product development and commercialization.
• Commercialization Roadmap: Clinical studies planned for 2025, with commercialization targeted for 2026.

Berkshire Biomedical is developing secure, biometric-controlled medication management solutions to address critical needs in chronic disease treatment, particularly for Opioid Use Disorder (OUD). Its flagship product, COPA, is a patented device designed to enhance medication adherence and patient safety through dual biometric verification and remote monitoring. With a $2M NIH grant supporting its development, the company is actively engaged in FDA pre-submission discussions and preparing for clinical studies in 2025. The goal is to commercialize COPA in 2026, making at-home treatment more accessible and reducing the burden of in-clinic dosing for controlled medications.

The funds raised in this offering will support regulatory filings, clinical validation, and commercialization efforts. By leveraging a secure dispensing platform and a recurring revenue model from device sales and consumables, Berkshire Biomedical aims to disrupt traditional medication management and expand into broader chronic disease applications. With strong intellectual property, a leadership team experienced in healthcare innovation, and growing market demand for better medication adherence solutions, the company is positioned to make a meaningful impact on patient care while creating long-term value for investors.

Company Info

Berkshire Biomedical develops COPA, a biometric-controlled medication dispensing system designed to improve Opioid Use Disorder treatment through secure, at-home self-administration.

Berkshire Biomedical is a medical technology company dedicated to developing secure and personalized medication management systems. Their flagship product, COPA, is designed to offer biometric-controlled dispensing of liquid oral medications, specifically targeting Opioid Use Disorder (OUD) management. COPA aims to address critical gaps in OUD treatment by enabling secure, at-home self-administration with dual biometric verification, which improves patient adherence and retention. The system also integrates remote monitoring to provide real-time data to healthcare providers, helping optimize treatment decisions and enhance oversight.

The company has completed five years of research and development, supported by a $2M NIH grant, and has filed for 19 patents to protect its intellectual property. Berkshire Biomedical is working with the FDA to prepare for COPA’s marketing authorization and clinical studies slated for 2025. The company is poised to make a significant impact in the OUD treatment space, with the potential for future expansion into other chronic disease treatments such as pain management. Berkshire’s strong leadership team, backed by decades of experience in healthcare innovation, is well-positioned to bring COPA to market and address the growing need for secure and accessible medication management.